Reporter: Aviva Lev-Ari, PhD, RN
Harnessing New Players in Atherosclerosis to Treat Heart Disease
Tuesday, September 24, 2013 | 8:30 AM – 4:30 PM
The New York Academy of Sciences
Presented by the Biochemical Pharmacology Discussion Group
Atherosclerosis is defined as a chronic inflammatory disease affecting arterial blood vessels involving dysregulation of the endothelial-leukocyte adhesive interactions, increased leukocyte apoptosis within the plaque, and defective phagocytosis of apoptotic cells. Despite the key role of monocytes/macrophages in atherosclerosis, mounting evidence suggests that dysregulation of other cell types may be independent risk factors for atherosclerosis. Leukocytes are produced daily and are derived from hematopoietic stem and progenitor cells within the bone marrow in a process call hematopoiesis. A better understanding of this process will open an avenue to identify new targets to fight atherosclerosis.
*Reception to follow.
Organizers
Mercedes Beyna, MS
Pfizer Global Research and Development
Nadeem Sarwar, PhD
Pfizer Global Research and Development
Laurent Yvan-Charvet, PhD
INSERM U1065/UNS, C3M
Jennifer Henry, PhD
The New York Academy of Sciences
Speakers
Elena V. Galkina, MD, PhD
Eastern Virginia Medical School
Emmanuel L. Gautier, PhD
Washington University School of Medicine, St. Louis
Klaus Ley, MD
La Jolla Institute for Allergy and Immunology
Andrew H. Lichtman, MD, PhD
Brigham and Women’s Hospital, Harvard Medical School
Kathryn J. Moore, PhD
New York University Medical Center
Matthias Nahrendorf, MD, PhD
Harvard Medical School
Alan R. Tall, MD, PhD
Columbia University Medical Center
http://www.nyas.org/Events/Detail.aspx?cid=1103f191-2d94-4f37-b91f-64293dc88019
Leave a Reply